A phase I, Dose escalation study of oral ASP8273 in patients with non–small cell lung cancers with epidermal growth factor receptor mutations.
Clinical Cancer Research.
Times cited: 11
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: A single-group, multicentre, phase 2 trial.
The Lancet Oncology.
Times cited: 355
Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer.
Times cited: 40
Systemic therapy of bronchioloalveolar carcinoma: Results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
Journal of Thoracic Oncology.
Times cited: 22